CClinicalTrials.gg
RecruitingNCT06737926Updated Dec 17, 2024

Effects of Sensorimotor Training With Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients

An interventional study of Sensorimotor Training Exercise and Conventional Exercise Therapy in Chemotherapy Induced Peripheral Neuropathy and Breast Cancer Patients, sponsored by Riphah International University. Recruiting at 2 sites in Pakistan. Open to female participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Jan 2024, registered Dec 2024).
  • Started Jan 2024; still recruiting 2 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
Female
01

Study summary

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a prevalent and clinically relevant side effect of chemotherapy in breast cancer patients. It occurs in 30-70% of cases. It can cause various sensory and motor symptoms. Specific exercise interventions have proven promising to target relevant symptoms. Therefore, the objective of this study is to determine the effects of Sensorimotor training on pain intensity, perceived balance confidence, and functional exercise capacity with chemotherapy-induced peripheral neuropathy in breast cancer patients.

Read the detailed description

The study incorporated a single blinded randomized controlled trial conducted at Mayo Hospital, Lahore. It involved 22 participants (N=22) recruited by using non-probability convenience sampling technique according to inclusion criteria and randomly allocated into either of two groups (Experimental group or Control group) using randomizer.org. The participants in experimental group performed sensorimotor training based on progressively challenging balance exercises on unstable surfaces. Participants performed three sets of exercises per session twice a week for 6 weeks, 45 minutes per session. The control group performed conventional exercises such as range of motion, stretching, strengthening, deep breathing and aerobic exercises for 2 times a week for 6 weeks, 45 minutes per session. Pre and post assessment of participants was done on numeric pain rating scale for pain intensity, TUG test for balance, activities-specific balance confidence scale for perceived balance confidence, 6-minute walk test for functional exercise capacity and EORTC QLQ C-30 for quality of life.

02

Conditions studied

  • Chemotherapy Induced Peripheral Neuropathy
  • Breast Cancer Patients

Keywords

  • Breast Cancer
  • Chemotherapy-Induced Peripheral Neuropathy
  • Postural Balance
  • Sensorimotor Neuropathy
  • Exercise
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's planned enrollment of 24 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,133 studies on the registry; 633 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Females with invasive ductal carcinoma, stages I-III
  • Age ranged between 30-65 years
  • 3-6 months post breast cancer diagnosis
  • Those who have completed chemotherapy treatment and are medically stable
  • CIPN symptoms as subjectively assessed by FACT/GOG-Ntx. Score ranges from 0-44 (5). 0 - 10: Minimal or no neurotoxicity symptoms, 11 - 20: Mild neurotoxicity symptoms, 21 - 30: Moderate neurotoxicity symptoms, 31 - 40: Severe neurotoxicity symptoms, 41 - 44: Very severe neurotoxicity symptoms
  • For balance testing Fullerton Advanced Balance (FAB) scale was used. 0-19 = high risk of falls, 20-29 = moderate balance impairment, 30-40 = good balance. The cut off value is ≤ 25/40 Points.
  • Objective neurological testing such as Achilles and patellar tendon reflexes (1 = agile, 2 = weak, 3 = missing), peripheral deep sensitivity (0=no sensitivity to 8=highest sensitivity), light touch perception (symmetrical or impaired), sense of position (1 = position recognized, 2 = only position of knee recognized, and 3 = no recognition) and lower leg strength (0 = no activity to 5 = normal force) rated on a Likert-scale

Exclusion criteria

Exclusion Criteria:

  • Women with additional types of cancer besides breast cancer
  • Chronic medical conditions such as poorly controlled diabetes (6)
  • Significant neurological (multiple sclerosis) or cardiopulmonary disease (myocardial infarction \< 3 months) that may affect performance (6)
  • Unstable bone metastasis
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Group A: Experimental Group receiving Sensorimotor Training Exercise.

    Participants will undergo sensorimotor training exercises targeting balance, pain reduction, and functional exercise capacity.

    Behavioral: Sensorimotor Training Exercise

  • Active comparator
    Group B: Control Group receiving Conventional Exercise Therapy.

    Participants will receive conventional exercise therapy as per standard guidelines.

    Behavioral: Conventional Exercise Therapy

Interventions

  • BehavioralSensorimotor Training Exercise

    Participants will perform sensorimotor training exercises designed to improve balance, reduce pain intensity, and enhance functional exercise capacity. The program will include progressive exercises focusing on proprioception, neuromuscular coordination, and functional mobility. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.

  • BehavioralConventional Exercise Therapy

    Participants will undergo conventional exercise therapy, including stretching, strengthening, and aerobic exercises, based on standard physiotherapy protocols. The therapy aims to maintain joint mobility, reduce stiffness, and improve general physical fitness. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.

06

What researchers measure

Primary outcomes

  1. Numeric Pain Rating Scale (NPRS)

    It is a uni-dimensional subjective measure of pain intensity in adults, including those with cancer pain. Zero usually represents 'no pain at all' whereas the upper limit represents 'the worst pain ever possible.

    Time frame: 6 weeks

  2. TUG Test

    It is used to determine the fall risk and measure the progress of balance. Mobility and balance is assessed based on time to complete the test: \< 10 seconds = normal. \< 20 seconds = good mobility \< 30 seconds = walking and balance problems

    Time frame: 6 weeks

  3. Activities-Specific Balance Confidence Scale

    The ABC-Scale is a self-reported assessment of the participant's level of confidence in static and dynamic balance while doing functional activities

    Time frame: 6 weeks

  4. 6-Minute Walk Test

    The 6-minute walk test (6MWT) is a standardized field test used to predict cardio-respiratory fitness in healthy individuals, as well as to assess functional exercise capacity and responsiveness to rehabilitation treatments in a variety of patient groups

    Time frame: 6 weeks

Secondary outcomes

  1. Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX) Subscale

    The FACT/GOG Ntx subscale is designed to measure chemotherapy-induced PN. It contains 11 items covering sensory neuropathy, motor neuropathy, hearing neuropathy, and dysfunction associated with neuropathy

    Time frame: 6 weeks

  2. EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)

    The EORTC QLQ-C30 is composed of nine multi-item scales: 5 functioning scales (physical, role, cognitive, emotional and social), a global QOL scale, and 3 symptom scales (fatigue, pain and nausea/vomiting).

    Time frame: 6 weeks

  3. Fullerton Advanced Balance Scale (FAB Scale)

    It is a screening tool which can be used in different group. It has long form (consisting of 10 tasks) and a short form (consisting of 4 tasks). The scale consists of a 5-point Likert scale from 0-4.

    Time frame: 6 weeks

07

Study locations

2 of 2 sites recruiting
  • Mayo Hospital Lahore
    Lahore, Punjab 54000, Pakistan
    Recruiting
  • Mayo Hospital
    Lahore, Punjab 54000, Pakistan
    Recruiting
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06737926
Lead sponsor
Riphah International University
Responsible party
Sponsor
First posted
Dec 17, 2024
Start date
Jan 15, 2024
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Dec 17, 2024

Study contacts

Imran Amjad, PHD
Contact
imran.amjad@riphah.edu.pk
03324390125
Muhammad Asrar Yousaf, M.phil
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion